The Top 5 Biosimilars Articles for the Week of January 28
The Center for Biosimilars® recaps the top news for the week of January 28, 2019.
Transcript:
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of January 28.
Number 5: The UK National Health Service has issued updated information on citrates in available biosimilar adalimumab.
Number 4: In observational studies of patients who have switched treatment from a reference biologic to a biosimilar, some higher rates of discontinuation may be related to the nocebo effect.
Number 3: During the CBI’s 14th Biosimilars Summit, the head of the FDA practice at Avalere said that enabling a global reference product for biosimilars would provide global access for patients.
Number 2: Bio-Thera Solutions announced that it has dosed the first patients in its phase 3 clinical study of BAT1806, a proposed biosimilar tocilizumab referencing Actemra.
Number 1: Coherus announced this week that it has become the latest biosimilar developer to settle with AbbVie, maker of brand-name adalimumab, Humira, over a proposed biosimilar. In an intellectual property twist, Coherus also announced that it has sued a rival biosimilar developer, Amgen.
Finally, last week, our e-newsletter asked if the confusion around the terms interchangeability, automatic substitution, and physician-mediated switching leads to reduced acceptance of biosimilars.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
